Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) insider Stefan K.F. Schwabe sold 95,000 shares of the company’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $46.59, for a total value of $4,426,050.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Supernus Pharmaceuticals, Inc. (NASDAQ SUPN) opened at 47.90 on Thursday. Supernus Pharmaceuticals, Inc. has a 1-year low of $17.25 and a 1-year high of $49.95. The firm has a market cap of $2.43 billion, a price-to-earnings ratio of 24.17 and a beta of 1.30. The firm has a 50-day moving average price of $43.82 and a 200 day moving average price of $37.23.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.08. The company had revenue of $75.83 million for the quarter, compared to the consensus estimate of $68.54 million. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%. Equities analysts predict that Supernus Pharmaceuticals, Inc. will post $1.04 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/09/14/supernus-pharmaceuticals-inc-supn-insider-sells-4426050-00-in-stock.html.

SUPN has been the topic of several analyst reports. Piper Jaffray Companies reissued a “hold” rating and issued a $45.00 target price on shares of Supernus Pharmaceuticals in a research note on Friday, September 8th. BidaskClub raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 17th. Jefferies Group LLC reissued a “buy” rating and issued a $51.00 target price on shares of Supernus Pharmaceuticals in a research note on Friday, August 4th. Cowen and Company reissued a “positive” rating and issued a $50.00 target price (up previously from $40.00) on shares of Supernus Pharmaceuticals in a research note on Thursday, August 3rd. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $47.00 target price (up previously from $36.00) on shares of Supernus Pharmaceuticals in a research note on Tuesday, July 18th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $48.29.

Several large investors have recently made changes to their positions in SUPN. Meeder Asset Management Inc. lifted its stake in shares of Supernus Pharmaceuticals by 3,455.2% in the 2nd quarter. Meeder Asset Management Inc. now owns 2,382 shares of the specialty pharmaceutical company’s stock valued at $103,000 after purchasing an additional 2,315 shares during the period. Ameritas Investment Partners Inc. acquired a new position in shares of Supernus Pharmaceuticals in the 1st quarter valued at about $127,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Supernus Pharmaceuticals by 278.2% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock valued at $130,000 after purchasing an additional 2,220 shares during the period. Riverhead Capital Management LLC lifted its stake in shares of Supernus Pharmaceuticals by 91.4% in the 2nd quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock valued at $132,000 after purchasing an additional 1,462 shares during the period. Finally, Advisor Group Inc. lifted its stake in shares of Supernus Pharmaceuticals by 13.7% in the 2nd quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock valued at $145,000 after purchasing an additional 410 shares during the period. 95.38% of the stock is currently owned by institutional investors.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Insider Buying and Selling by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.